Your browser doesn't support javascript.
loading
Asparaginase: How to Better Manage Toxicities in Adults.
Pourhassan, Hoda; Douer, Dan; Pullarkat, Vinod; Aldoss, Ibrahim.
Afiliação
  • Pourhassan H; City of Hope Medical Center, Duarte, CA, 90630, USA.
  • Douer D; University of Southern California, Los Angeles, CA, USA.
  • Pullarkat V; City of Hope Medical Center, Duarte, CA, 90630, USA.
  • Aldoss I; City of Hope Medical Center, Duarte, CA, 90630, USA. ialdoss@coh.org.
Curr Oncol Rep ; 25(1): 51-61, 2023 01.
Article em En | MEDLINE | ID: mdl-36449117
ABSTRACT
PURPOSE OF REVIEW This review aims to help oncologists who predominantly treat adults better understand and manage asparaginase associated toxicities and prevent unnecessary discontinuation or reluctance of its use. RECENT

FINDINGS:

Given the data supporting the benefit of incorporating multiple doses of asparaginase in pediatric type regimens, it is prudent to promote deeper understanding of this drug, particularly its toxicities, and its use so as to optimize treatment of ALL. Although asparaginase is associated with a variety of toxicities, the vast majority are not life threatening and do not preclude repeat dosing of this important drug. Understanding the pharmacology and toxicity profile of asparaginase is critical to dosing asparaginase appropriately in order to minimize these toxicities.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Limite: Adult / Child / Humans Idioma: En Revista: Curr Oncol Rep Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Limite: Adult / Child / Humans Idioma: En Revista: Curr Oncol Rep Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos